Study: Use of CBD in COVID-19 treatment

May 13, 2020

Various studies have already shown that cannabidiol (CBD) can have anti-inflammatory properties. According to a media report, researchers from Tel Aviv University are now conducting several clinical studies to investigate the use of CBD in the respiratory disease, COVID-19.

As COVID-19 affects the respiratory system, researchers will administer CBD-enriched exosomes to affected patients through an inhaler. Previous studies have already shown that CBD can possibly help to regulate the immune system and inhibit inflammation. The researchers assume that the anti-inflammatory properties of CBD could repair the damaged cells through a synergistic effect. 

Another clinical trial is being conducted in COVID-19 patients currently being treated at Rabin Medical Center in Israel. Here, the researchers will combine inhalable steroids with CBD, as CBD may be able to improve the effect of the steroids. 

In addition, it will be investigated whether cannabis, with all its cannabinoids, might possibly be able to slow down or stop COVID-19. 


Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.



CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg, Germany


Rosenthaler Str. 34
10178 Berlin

Gran de Gràcia 15, 1-1
08012 Barcelona